Researchers continue to excited about the medication , a novel dual agonist showing significant results in initial trials for weight loss . It acts by impacting both pathways : GLP-1 and GIP, that , https://phoebebmfw747492.blogdemls.com/40604331/a-new-possibility-for-body-management